Drug Search Results
More Filters [+]

Telaglenastat

Alternative Names: telaglenastat, cb-839
Latest Update: 2024-06-04
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: GLS Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Calithera Biosciences
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Susan M. Molineaux
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Telaglenastat

Countries in Clinic: United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Cervical Cancer|Colorectal Cancer|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Uterine Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

R01CA181745

P2

Not yet recruiting

Cervical Cancer|Uterine Cancer

2030-10-07

VICC GI 1703

P2

Active, not recruiting

Colorectal Cancer

2023-12-01

CX-839-012

P2

Completed

Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

2021-09-24

23%

Recent News Events